Interactive Global Value Dossiers: turning evidence into market access impact

As the volume of evidence increases, the real challenge is no longer access to data; but how effectively that data is communicated to diverse stakeholders in a way that drives meaningful engagement and action. The Global Value Dossier is a pivotal tool that helps consolidate the clinical, economic, humanistic, and regulatory evidence for a healthcare product into a single, structured value proposition.

A Global Value Dossier is a comprehensive, evidence-based document that consolidates critical information about a pharmaceutical or medical device product. Think of it like a guidebook that brings together all the important details in one place.  Historically, health value dossiers have been delivered as PDFs with a companion slide deck summarizing the value story.

This approach worked well enough when most engagements were face-to-face and the evidence base was more contained. But the reality of market access engagement has shifted, and static formats haven’t kept pace with that change.

The interactive Global Value Dossier (iGVD) transforms it from a static reference document into a fit-for-purpose tool. By making evidence navigable and adaptable, the iGVD ensures relevance for every stakeholder, and shifts the engagement from passive reading to active decision-making.

This layered approach allows users to follow a clear value narrative while drilling down into the underlying data as needed. With explorable economic models, stakeholders can tailor assumptions to their local environment. This creates a versatile, ‘single source of truth’ that powers multiple channels, without redundant effort.

Moving from a static Global Value Dossier value dossier to an actionable one requires more than just interactivity; it needs a strategic approach to adaptation across two distinct dimensions:

Starting from a comprehensive evidence base, teams must select, reduce, and reorder content based on the stakeholder and engagement format. Payer meetings require a narrative driven by budget impact and interactive models, while a HTA submission demands the full clinical and economic package.

Conversely, a KOL discussion thrives on a clinical deep-dive that invites dialogue. A digital self-service tool must surface key highlights for autonomous exploration. Each version is a curated “cut” of the same evidence, optimized for a specific engagement model.

The core framework must also reflect local realities. That includes varied comparators, local cost inputs, country-specific epidemiology, and regional reimbursement dynamics. This global-to-local dimension preserves strategic consistency while ensuring the evidence is relevant to each specific decision context.

BaseCase is a value communication platform purpose-built for pharma and life sciences. It bridges the gap between static data and actionable insights by connecting the four essential pillars of the interactive global value dossier lifecycle:

1. Create
2. Adapt
3. Distribute
4. Measure

BaseCase apps integrate clinical data, economic models and supporting evidence into structured, interactive experiences. By layering content, you ensure the core value story remains front-and-center, while keeping technical depth accessible on demand.

Because economic models are interactive, stakeholders can input their own data to explore budget impact and cost-effectiveness in real-time. This shifts the conversation from passive observation to proactive decision-making. Now decision makers experience your value proposition from their own unique perspective.

BaseCase makes the ‘dual-axis’ approach practical through a no-code environment that allows for rapid duplication and modification:

• Along the audience axis, teams can create focused versions of an app (selecting and resequencing content for a payer budget discussion, an HTA review, a KOL engagement, or a self-service summary) without rebuilding the underlying evidence structure.
• Along the geographic axis, global teams build the strategic foundation (the narrative structure, the model architecture, the evidence framework). Local affiliates deploy versions with market-specific comparators, pricing, language, and regulatory context.
• Core messaging stays consistent with your strategy. The details reflect each stakeholder’s specific reality.

Stakeholders engage with evidence differently. BaseCase provides distribution matched to each scenario enabling:

• Face-to-face and structured engagements, where teams guide stakeholders through the value story interactively.
• Controlled access for selected external audiences (payers, HTA bodies, advisory board members) with role-based permissions, enabling independent, on-demand review
• Interactive tools can be embedded into websites or shared without credentials, reaching broader audiences such as Medical Societies or Patient Advocacy Groups through public links.
• The same evidence base supports payer meetings, remote KOL discussions, and self-service exploration: one value narrative adapted to every context.

BaseCase analytics show how stakeholders interact with value communication tools, what content is viewed, which models are explored, and how engagement varies across audiences and markets. This helps teams refine their approach, identify what resonates, and quantify the reach of their market access communications.

The ultimate goal of a Global Value Dossier remains the same: translating evidence into decisions. However, as the stakeholder landscape grows more complex, methods must evolve to keep pace.

By strategically adapting evidence along both audience and geographic axes, platforms like BaseCase allow market access teams to move beyond static documentation to true engagement across every channel and market. The result: teams can create once, adapt easily, distribute widely, and maximize impact.